2,236 press releases in English indexed under biotech & pharma.
FDA grants Rare Pediatric Disease Designation to QRX003 for Peeling Skin Syndrome, Quoin's second RPD and a potential second Priority Review Voucher
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection
SUNNYVALE, Calif., Sept. 8, 2026 -- Anitoa Systems, LLC., a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing hardware, today announced a major advancement in point-of-care molecular testing: the integration of comprehensive cloud...
The case alleges Regeneron and its top executives made false and/or misleading statements to investors.
SHANGHAI, Sept. 8, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its...
SARASOTA, Fla., Sept. 8, 2026 -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...
Lindus Therapeutics names Dr. Gillian Cannon, former Merck and Roivant commercial leader, to its board as a non-executive director.
STOUGHTON, Mass., Sept. 08, 2026 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:
SAN DIEGO, Sept. 08, 2026 -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
BOSTON, Sept. 08, 2026 -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 14, 2026, at 1:50-2:25 p.m. ET.
NEW YORK, Sept. 08, 2026 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company’s clinical development strategy and priorities.
MIAMI, Sept. 08, 2026 -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on Friday, September 11, 2026, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference taking place September 14-16, 2026.